Juvenescence Amends AgeX Therapeutics Stake (Amendment No. 30)

TL;DR

**Big investor Juvenescence just updated their AgeX Therapeutics stake, watch for market reaction!**

AI Summary

Juvenescence Limited, a major shareholder in AgeX Therapeutics, Inc., filed an Amendment No. 30 to its Schedule 13D on January 16, 2024. This filing indicates a change in their beneficial ownership of AgeX Therapeutics' Common Stock, par value $0.0001 per share. This matters to investors because significant changes in ownership by large institutional holders like Juvenescence can signal shifts in confidence or strategic direction for AgeX Therapeutics, potentially influencing stock price and future corporate actions.

Why It Matters

This filing updates the public on a significant shareholder's position, which can influence investor sentiment and the perceived stability of AgeX Therapeutics' ownership structure.

Risk Assessment

Risk Level: medium — Changes in major shareholder positions can introduce uncertainty or signal potential strategic shifts, which carries a medium level of risk for current and prospective investors.

Analyst Insight

Investors should monitor subsequent filings from Juvenescence Limited to understand the nature of their ongoing involvement with AgeX Therapeutics, as significant changes in ownership can precede strategic shifts or impact stock performance.

Key Numbers

• $0.0001 — Par Value per Share (The nominal value of AgeX Therapeutics' Common Stock.)
• 30 — Amendment Number (Indicates this is the 30th amendment to Juvenescence Limited's Schedule 13D filing for AgeX Therapeutics, suggesting ongoing active management of their position.)

Key Players & Entities

• Juvenescence Limited (company) — the reporting person and major shareholder
• AgeX Therapeutics, Inc. (company) — the subject company whose securities are being reported
• David Gill (person) — authorized to receive notices for Juvenescence Limited
• $0.0001 (dollar_amount) — par value per share of AgeX Therapeutics Common Stock
• January 16, 2024 (date) — date of event requiring the filing

Forward-Looking Statements

• Juvenescence Limited will continue to actively manage its stake in AgeX Therapeutics, potentially leading to further amendments. (Juvenescence Limited) — high confidence, target: next 12 months
• The stock price of AgeX Therapeutics, Inc. may experience short-term volatility following the disclosure of this amendment. (AgeX Therapeutics, Inc.) — medium confidence, target: next 1 week

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $500,000 — Issuer each in the principal amount of $500,000. SIGNATURES After reasonable inquiry

Filing Documents

• tm242510d2_sc13da.htm (SC 13D/A) — 40KB
• 0001104659-24-004483.txt ( ) — 41KB

of the Original Statement is hereby amended and restated in

Item 5 of the Original Statement is hereby amended and restated in its entirety to read as follows: (a)The Reporting Persons beneficially owns an aggregate of 88,488,113 shares of Common Stock, representing (i) 16,447,500 shares of Common Stock held directly by JuvVentures (UK) Limited, (ii) 572,417 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the New Facility (as defined below), (iii) 10,357,086 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the A&R Secured Note (as defined below), (iv) 29,388,888 shares of Common Stock held directly by JuvVentures (UK) Limited that may be issued upon conversion of 211,600 shares of Series A Preferred Stock, (v) 20,611,111 shares of Common Stock held directly by JuvVentures (UK) Limited that may be issued upon conversion of 148,400 shares of Series B Preferred Stock and (vi) 11,111,111 shares of Common Stock that may be issued upon conversion of outstanding amounts under the A&R Secured Note at the closing price of the Common Stock on January 12, 2024 . This aggregate amount represents approximately 80.4% of the Issuer’s outstanding common stock, based upon 37,951,261 shares outstanding as of November 6, 2023, as reported on the Issuer’s Annual Report filed on Form 10-Q on November 14, 2023, and giving effect to the exercise of the Warrants and conversion of amounts outstanding under the A&R Secured Note and the Spring 2023 Note (and assuming the Amendment Caps do not apply). (b)The information in Items 7 through 10 of each cover page is incorporated by reference into this Item 5(b). (c)Except for the information set forth in Item 6, which is incorporated by reference into this Item 5(c), the Reporting Persons have effected no transactions relating to the Common Stock during the past 60 days. (d) - (e) Not applicable. Item 6. Contracts, Arrangements, Understa

of the Original Statement is hereby supplemented as follows

Item 6 of the Original Statement is hereby supplemented as follows: On January 16, 2024, the Reporting Person funded additional advances to the Issuer each in the principal amount of $500,000.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct. Date: January 17, 2024 JUVENESCENCE LIMITED By: /s/ Gregory H. Bailey Name: Gregory H. Bailey Title: Executive Chairman Date: January 17, 2024 JuvVentures (UK) Limited By: /s/ David Gill Name: David Gill Title: Director

View Full Filing

View this SC 13D/A filing on SEC EDGAR